Anika Therapeutics Inc
NASDAQ:ANIK

Watchlist Manager
Anika Therapeutics Inc Logo
Anika Therapeutics Inc
NASDAQ:ANIK
Watchlist
Price: 16.97 USD -2.64% Market Closed
Market Cap: 248.6m USD
Have any thoughts about
Anika Therapeutics Inc?
Write Note

Intrinsic Value

The intrinsic value of one ANIK stock under the Base Case scenario is 12.71 USD. Compared to the current market price of 16.97 USD, Anika Therapeutics Inc is Overvalued by 25%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

ANIK Intrinsic Value
12.71 USD
Overvaluation 25%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Anika Therapeutics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for ANIK cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about ANIK?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Anika Therapeutics Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Anika Therapeutics Inc

Provide an overview of the primary business activities
of Anika Therapeutics Inc.

What unique competitive advantages
does Anika Therapeutics Inc hold over its rivals?

What risks and challenges
does Anika Therapeutics Inc face in the near future?

Has there been any significant insider trading activity
in Anika Therapeutics Inc recently?

Summarize the latest earnings call
of Anika Therapeutics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Anika Therapeutics Inc.

Provide P/S
for Anika Therapeutics Inc.

Provide P/E
for Anika Therapeutics Inc.

Provide P/OCF
for Anika Therapeutics Inc.

Provide P/FCFE
for Anika Therapeutics Inc.

Provide P/B
for Anika Therapeutics Inc.

Provide EV/S
for Anika Therapeutics Inc.

Provide EV/GP
for Anika Therapeutics Inc.

Provide EV/EBITDA
for Anika Therapeutics Inc.

Provide EV/EBIT
for Anika Therapeutics Inc.

Provide EV/OCF
for Anika Therapeutics Inc.

Provide EV/FCFF
for Anika Therapeutics Inc.

Provide EV/IC
for Anika Therapeutics Inc.

Show me price targets
for Anika Therapeutics Inc made by professional analysts.

What are the Revenue projections
for Anika Therapeutics Inc?

How accurate were the past Revenue estimates
for Anika Therapeutics Inc?

What are the Net Income projections
for Anika Therapeutics Inc?

How accurate were the past Net Income estimates
for Anika Therapeutics Inc?

What are the EPS projections
for Anika Therapeutics Inc?

How accurate were the past EPS estimates
for Anika Therapeutics Inc?

What are the EBIT projections
for Anika Therapeutics Inc?

How accurate were the past EBIT estimates
for Anika Therapeutics Inc?

Compare the revenue forecasts
for Anika Therapeutics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Anika Therapeutics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Anika Therapeutics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Anika Therapeutics Inc compared to its peers.

Compare the P/E ratios
of Anika Therapeutics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Anika Therapeutics Inc with its peers.

Analyze the financial leverage
of Anika Therapeutics Inc compared to its main competitors.

Show all profitability ratios
for Anika Therapeutics Inc.

Provide ROE
for Anika Therapeutics Inc.

Provide ROA
for Anika Therapeutics Inc.

Provide ROIC
for Anika Therapeutics Inc.

Provide ROCE
for Anika Therapeutics Inc.

Provide Gross Margin
for Anika Therapeutics Inc.

Provide Operating Margin
for Anika Therapeutics Inc.

Provide Net Margin
for Anika Therapeutics Inc.

Provide FCF Margin
for Anika Therapeutics Inc.

Show all solvency ratios
for Anika Therapeutics Inc.

Provide D/E Ratio
for Anika Therapeutics Inc.

Provide D/A Ratio
for Anika Therapeutics Inc.

Provide Interest Coverage Ratio
for Anika Therapeutics Inc.

Provide Altman Z-Score Ratio
for Anika Therapeutics Inc.

Provide Quick Ratio
for Anika Therapeutics Inc.

Provide Current Ratio
for Anika Therapeutics Inc.

Provide Cash Ratio
for Anika Therapeutics Inc.

What is the historical Revenue growth
over the last 5 years for Anika Therapeutics Inc?

What is the historical Net Income growth
over the last 5 years for Anika Therapeutics Inc?

What is the current Free Cash Flow
of Anika Therapeutics Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Anika Therapeutics Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Anika Therapeutics Inc

Current Assets 136.1m
Cash & Short-Term Investments 62.4m
Receivables 28.4m
Other Current Assets 45.4m
Non-Current Assets 95.3m
PP&E 71.8m
Intangibles 10.7m
Other Non-Current Assets 12.8m
Current Liabilities 25.5m
Accounts Payable 6.8m
Accrued Liabilities 18.6m
Other Current Liabilities 82k
Non-Current Liabilities 26m
Other Non-Current Liabilities 26m
Efficiency

Earnings Waterfall
Anika Therapeutics Inc

Revenue
164.2m USD
Cost of Revenue
-61.2m USD
Gross Profit
102.9m USD
Operating Expenses
-109.1m USD
Operating Income
-6.2m USD
Other Expenses
-91.4m USD
Net Income
-97.5m USD

Free Cash Flow Analysis
Anika Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

ANIK Profitability Score
Profitability Due Diligence

Anika Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
Declining ROIC
31/100
Profitability
Score

Anika Therapeutics Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

ANIK Solvency Score
Solvency Due Diligence

Anika Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Anika Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ANIK Price Targets Summary
Anika Therapeutics Inc

Wall Street analysts forecast ANIK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ANIK is 27.03 USD with a low forecast of 25.25 USD and a high forecast of 29.4 USD.

Lowest
Price Target
25.25 USD
49% Upside
Average
Price Target
27.03 USD
59% Upside
Highest
Price Target
29.4 USD
73% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for ANIK?

Click here to dive deeper.

Dividends

Anika Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for ANIK is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

ANIK Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Anika Therapeutics Inc Logo
Anika Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

249.4m USD

Dividend Yield

0%

Description

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. The company is headquartered in Bedford, Massachusetts and currently employs 297 full-time employees. The firm is focused on developing, manufacturing, and commercializing products based on its hyaluronic acid (HA) technology platform. The Company’s product include OA Pain Management product consists of Monovisc and Orthovisc, which is single and multi-injection, HA-based viscosupplement product, Cingal, and Hyvisc; Joint Preservation and Restoration product consists of bone preserving joint technologies, soft tissue repair and regenerative solutions, and Non-Orthopedic product consists of Hyalobarrier, an anti-adhesion barrier indicated for use after abdomino-pelvic surgeries. Hyalomatrix is used for the treatment of wounds, such as burns, ulcers, ears, nose and throat disorders, and ophthalmic products.

Contact

MASSACHUSETTS
Bedford
32 Wiggins Ave
+17814579000.0
www.anikatherapeutics.com

IPO

1985-05-16

Employees

297

Officers

President, CEO & Director
Dr. Cheryl Renee Blanchard Ph.D.
Senior VP & COO
Ms. Anne Nunes
Executive VP, General Counsel & Corporate Secretary
Mr. David Colleran J.D.
Executive Officer
Mr. Michael L. Levitz
Executive VP, CFO & Treasurer
Mr. Stephen D. Griffin
VP & Chief Accounting Officer
Mr. Ian W. McLeod
Show More
Vice President of Investor Relations, ESG & Corporate Communications
Mr. Mark Namaroff
Senior Vice President of International Sales & Marketing
Mr. James Chase
Vice President of Commercial & Corporate Development
Mr. Ben Joseph
Vice President of Human Resources
Ms. Lisa Funiciello
Show Less

See Also

Discover More
What is the Intrinsic Value of one ANIK stock?

The intrinsic value of one ANIK stock under the Base Case scenario is 12.71 USD.

Is ANIK stock undervalued or overvalued?

Compared to the current market price of 16.97 USD, Anika Therapeutics Inc is Overvalued by 25%.

Back to Top